FR3115682B1 - Compositions à base de méthyl-cyclodextrines pour le traitement et/ou la prévention de la stéatose hépatique - Google Patents

Compositions à base de méthyl-cyclodextrines pour le traitement et/ou la prévention de la stéatose hépatique Download PDF

Info

Publication number
FR3115682B1
FR3115682B1 FR2011361A FR2011361A FR3115682B1 FR 3115682 B1 FR3115682 B1 FR 3115682B1 FR 2011361 A FR2011361 A FR 2011361A FR 2011361 A FR2011361 A FR 2011361A FR 3115682 B1 FR3115682 B1 FR 3115682B1
Authority
FR
France
Prior art keywords
methyl
prevention
treatment
cyclodextrins
hepatic steatosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR2011361A
Other languages
English (en)
Other versions
FR3115682A1 (fr
Inventor
Daniel Wils
Caroline Perreau
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Roquette Freres SA
Original Assignee
Roquette Freres SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR2011361A priority Critical patent/FR3115682B1/fr
Application filed by Roquette Freres SA filed Critical Roquette Freres SA
Priority to PCT/EP2021/025430 priority patent/WO2022096151A1/fr
Priority to MX2023005255A priority patent/MX2023005255A/es
Priority to EP21805838.6A priority patent/EP4240371A1/fr
Priority to KR1020237018567A priority patent/KR20230093516A/ko
Priority to US18/251,358 priority patent/US20240000827A1/en
Priority to CA3197127A priority patent/CA3197127A1/fr
Priority to CN202180074737.6A priority patent/CN116456991A/zh
Priority to JP2023525452A priority patent/JP2023547633A/ja
Priority to AU2021374726A priority patent/AU2021374726A1/en
Publication of FR3115682A1 publication Critical patent/FR3115682A1/fr
Application granted granted Critical
Publication of FR3115682B1 publication Critical patent/FR3115682B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Abstract

La présente invention est relative à une nouvelle utilisation d’une composition pharmaceutique comprenant au moins une méthyl-cyclodextrine dans le traitement et/ou la prévention de la stéatose hépatique et maladies associées. Elle concerne également l’utilisation de méthyl-cyclodextrine pour réduire la stockage de lipides dans le foie.
FR2011361A 2020-11-05 2020-11-05 Compositions à base de méthyl-cyclodextrines pour le traitement et/ou la prévention de la stéatose hépatique Active FR3115682B1 (fr)

Priority Applications (10)

Application Number Priority Date Filing Date Title
FR2011361A FR3115682B1 (fr) 2020-11-05 2020-11-05 Compositions à base de méthyl-cyclodextrines pour le traitement et/ou la prévention de la stéatose hépatique
JP2023525452A JP2023547633A (ja) 2020-11-05 2021-11-04 脂肪肝の治療及び／又は予防のためのメチルシクロデキストリンを含む組成物
EP21805838.6A EP4240371A1 (fr) 2020-11-05 2021-11-04 Compositions a base de methyl-cyclodextrines pour le traitement et/ou la prevention de la steatose hepatique
KR1020237018567A KR20230093516A (ko) 2020-11-05 2021-11-04 간 지방증의 치료 및/또는 예방을 위한 메틸 사이클로덱스트린을 포함하는 조성물
US18/251,358 US20240000827A1 (en) 2020-11-05 2021-11-04 Compositions comprising methyl cyclodextrins for the treatment and/or prevention of hepatic steatosis
CA3197127A CA3197127A1 (fr) 2020-11-05 2021-11-04 Compositions a base de methyl-cyclodextrines pour le traitement et/ou la prevention de la steatose hepatique
PCT/EP2021/025430 WO2022096151A1 (fr) 2020-11-05 2021-11-04 Compositions a base de methyl-cyclodextrines pour le traitement et/ou la prevention de la steatose hepatique
MX2023005255A MX2023005255A (es) 2020-11-05 2021-11-04 Composiciones que comprenden metilciclodextrinas para el tratamiento y/o la prevencion de la esteatosis hepatica.
AU2021374726A AU2021374726A1 (en) 2020-11-05 2021-11-04 Compositions comprising methyl cyclodextrins for the treatment and/or prevention of hepatic steatosis
CN202180074737.6A CN116456991A (zh) 2020-11-05 2021-11-04 包含甲基环糊精的用于治疗和/或预防肝脂肪变性的组合物

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR2011361A FR3115682B1 (fr) 2020-11-05 2020-11-05 Compositions à base de méthyl-cyclodextrines pour le traitement et/ou la prévention de la stéatose hépatique
FR2011361 2020-11-05

Publications (2)

Publication Number Publication Date
FR3115682A1 FR3115682A1 (fr) 2022-05-06
FR3115682B1 true FR3115682B1 (fr) 2023-02-24

Family

ID=75278079

Family Applications (1)

Application Number Title Priority Date Filing Date
FR2011361A Active FR3115682B1 (fr) 2020-11-05 2020-11-05 Compositions à base de méthyl-cyclodextrines pour le traitement et/ou la prévention de la stéatose hépatique

Country Status (10)

Country Link
US (1) US20240000827A1 (fr)
EP (1) EP4240371A1 (fr)
JP (1) JP2023547633A (fr)
KR (1) KR20230093516A (fr)
CN (1) CN116456991A (fr)
AU (1) AU2021374726A1 (fr)
CA (1) CA3197127A1 (fr)
FR (1) FR3115682B1 (fr)
MX (1) MX2023005255A (fr)
WO (1) WO2022096151A1 (fr)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6602860B1 (en) 1999-11-12 2003-08-05 Josef Pitha Crystalline mixtures of partial methyl ethers of beta-cyclodextrin and related compounds
FR3014694B1 (fr) * 2013-12-13 2016-11-11 Roquette Freres Compositions a base de methyl-cyclodextrines pour le traitement et/ou la prevention de maladies par augmentation du taux de cholesterol-hdl
US10538487B2 (en) * 2015-02-16 2020-01-21 The University Of Queensland Sulfonylureas and related compounds and use of same
RO133396A0 (ro) * 2018-12-05 2019-06-28 Universitatea De Vest "Vasile Goldiş" Din Arad Sistem drug delivery crisină - random methyl - beta cyclodextrin () cu potenţial antifibrotic ridicat în prevenţia/regenerarea leziunilor fibrotice hepatice

Also Published As

Publication number Publication date
EP4240371A1 (fr) 2023-09-13
CA3197127A1 (fr) 2022-05-12
WO2022096151A1 (fr) 2022-05-12
JP2023547633A (ja) 2023-11-13
FR3115682A1 (fr) 2022-05-06
CN116456991A (zh) 2023-07-18
KR20230093516A (ko) 2023-06-27
US20240000827A1 (en) 2024-01-04
MX2023005255A (es) 2023-07-24
AU2021374726A1 (en) 2023-06-08

Similar Documents

Publication Publication Date Title
MA40814A1 (fr) Compositions pharmaceutiques pour thérapie combinée
MA52154B1 (fr) Composition pharmaceutique pour l'anémie
Steffel et al. The COMPASS trial: net clinical benefit of low-dose rivaroxaban plus aspirin as compared with aspirin in patients with chronic vascular disease
MA53076B1 (fr) Compositions solides comportant un agoniste glp-1, du sel d'acide n-(8-(2-hydroxybenzoyl)amino)caprylate et un lubrifiant
Deuter et al. Efficacy and tolerability of interferon alpha treatment in patients with chronic cystoid macular oedema due to non-infectious uveitis
Castilla-Guerra et al. Statins in stroke prevention: present and future
MA52680A1 (fr) Méthodes de réduction du besoin de revascularisation artérielle périphérique chez un sujet traité par des statines
MA30806B1 (fr) Phosphoindoles enantiomeriquement purs utilisables en tant qu'inhibiteurs du vih
FR3063645B1 (fr) Acefapc pour le traitement des maladies acetylcholine dependantes
MA29675B1 (fr) Nouvelle formulation pharmaceutique contenant un biguanide et un derive de thiazolidinedione
TNSN07426A1 (fr) Composition pharmaceutique comprenant un antiviral,un antitumoral ou un antiparasitaire, et un actif choisi parmi le carveol, le thymol, l'eugenol le borneol et le carvacrol
Chiu et al. Calpain and N-methyl-d-aspartate (NMDA)-induced excitotoxicity in rat retinas
FR3115682B1 (fr) Compositions à base de méthyl-cyclodextrines pour le traitement et/ou la prévention de la stéatose hépatique
MA46611A (fr) Traitements combinés comprenant des imidazopyrazinones pour le traitement de troubles psychiatriques et/ou cognitifs
MA29451B1 (fr) Association entre la ferroquine et un derive d'artemisinine pour le traitement du paludisme
Villalba-Pinto et al. Massive bilateral serous retinal detachment in a case of hypertensive chorioretinopathy
MA35363B1 (fr) Utilisation d'un composé organisation dans le traitement du syndrome de noonan
CA2739376A1 (fr) Composition stabilisee pour traiter le psoriasis
Kumaş et al. Protective effects of silymarin against isotretinoin induced liver and kidney injury in mice
Sardana et al. An observational analysis of low‐dose thalidomide in recalcitrant prurigo nodularis
Ashok et al. Necrotizing scleritis associated with rheumatoid arthritis: long-term remission with high-dose infliximab therapy
FR3092968B1 (fr) Complement alimentaire
Menezes et al. The effects of statins on prevention of stroke and dementia: a review
Rosenblit Lowering targeted atherogenic lipoprotein cholesterol goals for patients at “extreme” ASCVD risk
Rose et al. Dose-dependent induction of IL-6 by plant-derived proteases in vitro

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 2

PLSC Publication of the preliminary search report

Effective date: 20220506

PLFP Fee payment

Year of fee payment: 3

PLFP Fee payment

Year of fee payment: 4